No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MNMD240816C12000
- 0.10
- -0.05-33.33%
15min DelayClose Jul 22 15:49 ET
0.10High0.10Low
0.10Open0.15Pre Close7 Volume299 Open Interest12.00Strike Price70.00Turnover97.91%IV40.53%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1260Delta0.0933Gamma68.88Leverage Ratio-0.0092Theta0.0007Rho8.68Eff Leverage0.0047Vega
Intraday
- 5D
- Daily
News
Mind Medicine Says New Patent Secured for Investigational Anxiety Disorder Treatment MM120
Mind Medicine (MNMD) said Wednesday that the US Patent and Trademark Office has issued a new patent covering MM120, which is in clinical development for treating generalized anxiety disorder and
Express News | MindMed Announces PAtent Covering MM120 Orally Disintegrating Tablet
Express News | MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
Express News | Mind Medicine (MindMed) Inc - “at the Market Offering” Sales Agreement Prospectus Supplement Covering Offering of up to $150 Mln of Common Shares
Express News | Mind Medicine (MindMed) Inc Files for Mixed Shelf-SEC Filing
Express News | MindMed To Be Included In Russell 2000 And Russell 3000 Indexes, Effective Today
Comments
$Mind Medicine(MNMD.US$ Reuters· 3 mins ago
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
$Mind Medicine(MNMD.US$
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
$Mind Medicine(MNMD.US$ MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
4
$Seelos Therapeutics(SEEL.US$ $Cybin(CYBN.US$ $Mind Medicine(MNMD.US$ FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
5
13
Read more